GLP1R and Hypercholesterolemia: This leads to increased BA exposure and agonism of enteroendocrine L-cell TGR5, enhancing systemic GLP-1 secretion in mice.696 The enhanced GLP-1 secretion was correlated with improved insulin sensitivity and suppressed hepatic glycogenolysis in a DIO rat model.697,698 Alongside DIO rat models, this GLP-1 secretory outcome was found and validated in a systemic review of phase II human trials, serving as evidence for the potential usage of BA sequestrants not just for hypercholesterolemia but as an insulin-sensitizing and anorexic therapeutic.699–701